NO20074853L - Smamolekylinhibitorer av MDM2 og anvendelser derav - Google Patents

Smamolekylinhibitorer av MDM2 og anvendelser derav

Info

Publication number
NO20074853L
NO20074853L NO20074853A NO20074853A NO20074853L NO 20074853 L NO20074853 L NO 20074853L NO 20074853 A NO20074853 A NO 20074853A NO 20074853 A NO20074853 A NO 20074853A NO 20074853 L NO20074853 L NO 20074853L
Authority
NO
Norway
Prior art keywords
mdm2
inhibitors
smamolecule
applications
relates
Prior art date
Application number
NO20074853A
Other languages
English (en)
Inventor
Shaomeng Wang
Ke Ding
Yipin Lu
Zaneta Nikolovska-Coleska
Su Qiu
Guoping Wang
Dongguang Qin
Sanjeev Kumar
Original Assignee
Universtity Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universtity Of Michigan filed Critical Universtity Of Michigan
Publication of NO20074853L publication Critical patent/NO20074853L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen vedrører små molekyler i følge figur 1 som virker som inhibitorer av interaksjonen mellom p53 og MDM2. Oppfinnelsen vedrører også anvendelsen av disse forbindelsene til inhibering av cellevekst, indusering av celledød, indusering av cellesyklusstans og/eller sensitivisering av celler overfor ytterligere middel eller midler. (1)
NO20074853A 2005-02-22 2007-09-24 Smamolekylinhibitorer av MDM2 og anvendelser derav NO20074853L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65513505P 2005-02-22 2005-02-22
PCT/US2006/006221 WO2006091646A2 (en) 2005-02-22 2006-02-22 Small molecule inhibitors of mdm2 and uses thereof

Publications (1)

Publication Number Publication Date
NO20074853L true NO20074853L (no) 2007-11-21

Family

ID=36927977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074853A NO20074853L (no) 2005-02-22 2007-09-24 Smamolekylinhibitorer av MDM2 og anvendelser derav

Country Status (11)

Country Link
EP (1) EP1856123B1 (no)
JP (2) JP5248866B2 (no)
KR (1) KR100944301B1 (no)
CN (2) CN101160314B (no)
AU (2) AU2006216780B8 (no)
BR (1) BRPI0609172A2 (no)
CA (2) CA2598690C (no)
EA (2) EA014445B1 (no)
MX (1) MX2007010272A (no)
NO (1) NO20074853L (no)
WO (1) WO2006091646A2 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
SG174107A1 (en) * 2006-08-30 2011-09-29 Univ Michigan New small molecule inhibitors of mdm2 and the uses thereof
CN101516366B (zh) * 2006-09-21 2012-05-30 霍夫曼-拉罗奇有限公司 作为抗癌剂的羟吲哚衍生物
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
EP2103619A4 (en) 2006-12-14 2011-11-23 Daiichi Sankyo Co Ltd IMIDAZOTHIAZOLDERIVATE
PE20081897A1 (es) 2007-03-29 2009-02-09 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
WO2008144507A2 (en) * 2007-05-16 2008-11-27 President And Fellows Of Harvard College Spirooxindole inhibitors of aurora kinase
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) * 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) * 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
CA2734363C (en) * 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN105218565A (zh) 2008-10-17 2016-01-06 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CN102753556B (zh) 2009-10-14 2015-05-13 泽农医药公司 螺-羟吲哚化合物的合成方法
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
JP2013510860A (ja) * 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
NZ601667A (en) 2010-02-26 2014-10-31 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CA2800519A1 (en) * 2010-04-09 2011-10-13 The Regents Of The University Of Michigan Biomarkers for mdm2 inhibitors for use in treating disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120065210A1 (en) * 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
US20120071499A1 (en) * 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
CA2817585A1 (en) * 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
DK2684880T3 (en) * 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
ES2624808T3 (es) * 2011-05-11 2017-07-17 The Regents Of The University Of Michigan Antagonistas de MDM2 espirooxindólicos
CN102627650B (zh) * 2012-03-08 2015-07-08 徐州师范大学 手性四氢吡咯-3,2′-氧化吲哚螺环化合物及其合成方法
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CN103435622B (zh) * 2013-07-31 2015-11-18 陕西科技大学 一种螺环吲哚二酮哌嗪类生物碱及其合成方法和应用
KR102447057B1 (ko) 2013-09-04 2022-09-23 다이이찌 산쿄 가부시키가이샤 스피로옥시인돌 유도체의 제조 방법
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
ES2739697T3 (es) 2014-08-21 2020-02-03 Boehringer Ingelheim Int Nuevos compuestos y derivados de espiro[3H-indol-3,2-pirrolidin]-2(1H)-ona como inhibidores de MDM2-p53
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
EP3260119B1 (en) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Combination method for treating cancer
MY188957A (en) * 2015-03-30 2022-01-14 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
US10485794B2 (en) 2015-04-13 2019-11-26 Daiichi Sankyo Company, Limited Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
HRP20210960T1 (hr) 2015-10-09 2021-09-03 Boehringer Ingelheim International Gmbh Spojevi i derivati spiro[3h-indol-3,2’-pirolidin]-2(1h)-ona kao inhibitori mdm2-p53
CN105585570B (zh) * 2015-12-15 2019-10-15 贵州大学 异恶唑拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
JP7037500B2 (ja) * 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3527226A4 (en) 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN107353292B (zh) * 2017-08-23 2018-07-10 山东博苑医药化学有限公司 螺环氧化吲哚乙内酰（硫）脲衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法
CN110680838B (zh) * 2019-11-21 2021-10-01 海门茂发美术图案设计有限公司 一种素心腊梅碱的抗前列腺癌用途
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115417871B (zh) * 2022-09-21 2023-06-02 成都理工大学 双螺环吡咯螺氧化吲哚化合物及其合成方法和抗真菌活性
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) * 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) * 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
JPH0423184A (ja) * 1990-05-18 1992-01-27 Toshiba Corp 光学的文字読取装置
JP3074281B2 (ja) * 1990-05-30 2000-08-07 住友大阪セメント株式会社 フレキシブルコンテナ
JPH07238069A (ja) * 1994-02-28 1995-09-12 Daicel Chem Ind Ltd 環状アミド化合物の製造方法
RU2084449C1 (ru) * 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) * 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
WO1998031378A1 (de) * 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
PT994890E (pt) * 1997-06-10 2003-11-28 Glaxo Group Ltd Derivados de benzimidazole
US6114540A (en) * 1997-09-08 2000-09-05 Arqule, Inc. Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use
CN1182083C (zh) * 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
PL370909A1 (en) * 2001-12-18 2005-05-30 F.Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors

Also Published As

Publication number Publication date
AU2010202759B2 (en) 2012-07-19
AU2006216780B2 (en) 2010-04-01
CA2598690C (en) 2011-11-15
CA2752738A1 (en) 2006-08-31
EA014445B1 (ru) 2010-12-30
JP2008531504A (ja) 2008-08-14
KR100944301B1 (ko) 2010-02-24
AU2010202759A1 (en) 2010-07-22
CN102627649A (zh) 2012-08-08
CA2598690A1 (en) 2006-08-31
CN101160314B (zh) 2012-05-23
JP5638023B2 (ja) 2014-12-10
EA201001255A1 (ru) 2011-02-28
CN101160314A (zh) 2008-04-09
EP1856123A2 (en) 2007-11-21
EP1856123B1 (en) 2016-02-17
MX2007010272A (es) 2008-03-12
WO2006091646A2 (en) 2006-08-31
AU2006216780A1 (en) 2006-08-31
WO2006091646A3 (en) 2006-11-30
JP5248866B2 (ja) 2013-07-31
EA019566B1 (ru) 2014-04-30
CN102627649B (zh) 2015-03-25
AU2006216780B8 (en) 2010-04-22
EP1856123A4 (en) 2010-12-29
BRPI0609172A2 (pt) 2010-02-23
JP2012162550A (ja) 2012-08-30
CA2752738C (en) 2014-05-27
EA200701771A1 (ru) 2008-06-30
KR20070108917A (ko) 2007-11-13

Similar Documents

Publication Publication Date Title
MX2007010272A (es) Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
MX2009002306A (es) Nuevos inhibidores de mdm2 de molecula pequeña y sus usos.
NO20081042L (no) PPAR aktive forbindelser
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
NO20081160L (no) Benzimidazoltiofen forbindelser
NO20076001L (no) Tigecyklin og metoder for deres fremstilling
NO20075200L (no) Fremstilling av karotenoider i oljeaktige gjaer og fungi
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
NO20083153L (no) Kjemiske forbindelser
NO20076072L (no) Tigecyklin og metoder for fremstilling av 9-nitrominocyklin
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
BRPI0518752A2 (pt) 1-alquinil-2-arilàxi-alquil-amidas e uso do mesmo como fungicidas
NO20076391L (no) Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
AR061542A1 (es) Masa de absorcion y procedimiento para eliminar mercurio
SE0400208D0 (sv) Chemical compounds
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
GB0508314D0 (en) Organic compounds
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
BRPI0512310A (pt) compostos quìmicos
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application